Our Publications


 
    Noxopharm announced a research abstract has been published at ASCO 2022 which confirms lead drug candidate, Veyonda’s immunomodulatory properties against nasopharyngeal carcinoma, in combination with the chemotherapy cisplatin.  

Read More here.

 
    Noxopharm collaborators at Hudson confirm the relevance of TLR7 activation in Lupus validating the great potential of Noxopharm’s in-licenced molecules, comprising a new class of TLR7 inhibitors  

Read More here.

 
    The reputable Journal of Nuclear Medicine published Noxopharm’s LuPIN trial as its featured article with its results pictured on the cover of the journal’s April edition.  

177 Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial | Journal of Nuclear Medicine

 
    Poster presented at 2020 Annual Meeting of the Clinical Oncology Society of Australia (COSA), “Idronoxil combined with cisplatin rescues refractory immune responses in nasopharyngeal carcinoma  
 
    Publication in international journal (European Urology Oncology) strengthens case for Veyonda as a safe and possibly life-prolonging treatment in late-stage prostate cancer  
 
    DARRT-1 Interim Data Presented To Conference  
 
    LuPIN Data Being Presented To Conference  
 
    Abstract first published in the Journal of Nuclear Medicine. Interim results of the LuPIN trial. Oral presentation at the Society of Nuclear Medicine and Medical Imaging (SNMMI) Annual Meeting, June 2019 Anaheim CA  
 
    Trial in Progress: NOX66 in combination with Palliative Radiotherapy in patients with CRPC – a Phase 1 safety and dose finding study  

Poster at COSA Annual Meeting Perth November 2018

 
    A phase 1 study of NOX66 in combination with carboplatin in patients with end stage solid tumours  

Poster at COSA Annual Meeting Perth November 2018

 
    NOX66 and Palliative Radiotherapy in Patients with Late-Stage Prostate Cancer- A Phase 1b Proof of Concept and Dose Confirmation Study  

Poster presented at Australian and New Zealand Urogenital and Prostate Cancer (ANZUP) Clinical Trials Group Annual Scientific Meeting, Sydney. July 8-10 2018

 
    A phase 1 study of NOX66 in combination with carboplatin in patients with end stage solid tumours  
 
    NOX66 Plus Low Dose Carboplatin CEP-1 Study Interim Trial Results  
 
    NOX66 Plus Carboplatin - Phase 1 Signalling Study  
 
    ENOX2 levels of patients receiving NOX66  
 
    Idronoxil levels of patients receiving NOX66  
 
    Trial Design: Safety of NOX66 in Combination with Palliative Dose Radiotherapy - A Phase 1 Dose Escalation Study  
 
    Chemosensitization of Carboplatin by NOX66